Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.51 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.48 |
| ▸ | EDNRA | P25101 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20875874 | 1.00 | SLC6A3 (0.51) | SLC6A3SLC6A2EDNRASLC6A4AKR1C3 | |
| SCHEMBL20875940 | 1.00 | SLC6A3 (0.51) | SLC6A3SLC6A2EDNRASLC6A4AKR1C3 | |
| SCHEMBL20875878 | 0.86 | SLC6A3 (0.49) | SLC6A3SLC6A2EDNRASLC6A4SMN1; SMN2 | |
| SCHEMBL22279805 | 0.85 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4SMN1; SMN2 | |
| SCHEMBL20875899 | 0.80 | SLC6A3 (0.43) | SLC6A3SLC6A2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22279791 | 0.79 | MAPT (0.54) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL20875879 | 0.79 | MAPT (0.54) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL22279590 | 0.79 | MAPT (0.54) | SMN1; SMN2MEN1KMT2A | |
| SCHEMBL24039071 | 0.76 | GAA (0.44) | SLC6A3SLC6A2SMN1; SMN2MEN1KMT2A | |
| SCHEMBL11084872 | 0.76 | SLC6A3 (0.81) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-11-23 | — | — | US | disclosed |
| EP-3692035-A1 | ANTIVIRAL COMPOUNDS | Haplogen GmbH (AT) | 2020-08-12 | — | — | EP | disclosed |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2020-07-30 | — | — | US | disclosed |
| WO-2019068841-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2019-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180479-B2 | Antiviral compounds | PLA2G1B, PLA2G4A, PLA2G4C | SLC6A3 3736/4885SLC6A2 3284/4885EDNRA 2353/4885 |
| US-20200239446-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G4A, PLA2G4C | SLC6A3 3736/4885SLC6A2 3284/4885EDNRA 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.